Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor.
Xiaoshen Ma, David L Sloman, Ruchia Duggal...
https://pubmed.ncbi.nlm.nih.gov/38924388/Actively Recruiting
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-07
830
Participants Needed
75
Research Sites
N/A
Total Duration
Researchers are evaluating calderasib alone and in combination with other therapies for people with advanced solid tumors that have a specific KRAS G12C mutation. The study is designed to assess the safety, how the body processes the drug pharmacokinetics, and the effectiveness of calderasib and its combinations. Participants have advanced cancers confirmed by specific tests and have often received prior treatments. Participants are assigned to one of several groups receiving different treatments. Some receive daily oral doses of calderasib alone with doses increasing up to 800 mg, adjusted as needed for safety. Others receive calderasib combined with pembrolizumab infusions every 21 days for up to 35 cycles 24 months, sometimes with additional chemotherapy drugs like carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, or 5-fluorouracil according to standard dosing schedules. Treatments continue until the disease progresses or participants stop. During the study, participants have regular visits for drug dosing and safety monitoring. Researchers track side effects, dose-limiting toxicities, and treatment discontinuations over months. Blood samples are taken at specific times to measure drug levels and how the body absorbs and clears calderasib. The main outcomes include safety measures up to about 56 months and response rates. This long study period helps understand how participants respond and tolerate the treatments over time.
CONDITIONS
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
T
Toll Free Number
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Merck Sharp & Dohme LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Calderasib (MK-1084) alone or with combination therapy (as assigned by tumor type and line of therapy) | Current standard systemic therapies for advanced KRAS G12C-mutant tumors (NSCLC and CRC) |
|---|---|---|
| What it is | Experimental oral KRAS G12C inhibitor (Calderasib), studied as monotherapy and in combinations (with pembrolizumab, carboplatin/pemetrexed, cetuximab/chemo) per trial arm in adults with advanced or metastatic solid tumors harboring a KRAS G12C mutation. | Systemic cancer therapies recommended by current international guidelines for advanced/metastatic KRAS G12C-mutant tumors (e.g., immune checkpoint inhibitors plus chemotherapy for first-line NSCLC; doublet/triplet chemotherapy regimens and consideration of targeted agents for colorectal cancer), tailored by cancer type and prior treatment line. |
| Role in the trial | Calderasib is assigned in multiple arm cohorts, with dose and combination therapy varying according to tumor type (NSCLC, CRC, other) and line of therapy (untreated/metastatic, previously treated, combination vs monotherapy settings). | Guideline-recommended therapies are provided as first-line or subsequent-line systemic treatment options based on cancer type and prior treatments, including immunotherapy, chemotherapy (platinum-based, 5-FU–based), and, for eligible NSCLC patients, targeted agents; these serve as standard care outside clinical trials. |
| Primary use / intent | To evaluate safety, tolerability, and early efficacy (tumor response, pharmacokinetics) of Calderasib as monotherapy and in combination with standard agents in adults with advanced/metastatic solid tumors carrying a KRAS G12C mutation. | To provide optimal disease control and prolong survival using established systemic therapies, following international guidelines for the management of advanced/metastatic KRAS G12C-mutant solid tumors. First-line NSCLC: recommended regimens often combine platinum doublets with checkpoint inhibitor. For colorectal cancer: systemic chemo +/- biologics per mutational status. |
| How it is given or performed | Oral capsules (Calderasib) given daily as monotherapy or in combination, combined with intravenous checkpoint inhibitor (pembrolizumab) and/or chemotherapy (standard per agent label) depending on the arm. Doses and combinations vary by tumor type and arm assignment. | Systemic therapy is administered as prescribed: intravenous infusions for chemotherapy (platinum, 5-FU–based) and immunotherapies (e.g., pembrolizumab), given on standard cycles; oral agents may be included where available. Combination and sequence are dictated by cancer type, mutation, and guideline-defined line-of-therapy. |
| Evidence status / maturity | Early-phase clinical evidence is being collected; no peer-reviewed efficacy or mature outcome data published yet for Calderasib (MK-1084) in KRAS G12C-mutant tumors as of the present trial stage. | Multiple large trials and meta-analyses support the efficacy and clinical benefit of established regimens (immune checkpoint inhibitors, platinum-based doublets in NSCLC; combination chemotherapies and biologics in CRC) for the indicated lines and populations. |
| Important limitations | Trial arms are non-randomized, primarily early-phase dose, safety, and preliminary efficacy evaluation; diverse tumor types and arm-specific inclusion. No direct comparator arm for current standard of care; clinical benefit and risks remain investigational until further data are available. | Standard regimens have well-characterized limitations, including incomplete response rates, chemotoxicity, potential for resistance, and limited efficacy in KRAS G12C-driven disease. Patients with KRAS G12C tumors often have suboptimal long-term outcomes with standard care alone; novel prognostic and predictive markers are being investigated. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to about 24 months or until disease progression
Participants receive daily oral doses of calderasib alone or combined with other therapies such as pembrolizumab, chemotherapy drugs, and cetuximab according to their assigned group. Dose adjustments may be made for safety. Treatment continues until disease progression or discontinuation.
Regular visits for drug administration and monitoring
Duration - Up to about 56 months
Participants are monitored for safety, side effects, and treatment response. Blood samples are collected at specific times to measure drug levels and how the body processes calderasib.
Scheduled visits for assessments and laboratory tests
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Have more questions? Get in touch with our team for quick support
Xiaoshen Ma, David L Sloman, Ruchia Duggal...
https://pubmed.ncbi.nlm.nih.gov/38924388/Merck Sharp & Dohme LLC
Lead Sponsor